WO1998046225A1 - Method for treating schizophrenia - Google Patents
Method for treating schizophrenia Download PDFInfo
- Publication number
- WO1998046225A1 WO1998046225A1 PCT/US1998/007152 US9807152W WO9846225A1 WO 1998046225 A1 WO1998046225 A1 WO 1998046225A1 US 9807152 W US9807152 W US 9807152W WO 9846225 A1 WO9846225 A1 WO 9846225A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- disorder
- schizophrenia
- chronic
- unspecified
- subchronic
- Prior art date
Links
- XVFJONKUSLSKSW-JTQLQIEISA-N C#CCO[C@@H]1C(CC2)CCN2C1 Chemical compound C#CCO[C@@H]1C(CC2)CCN2C1 XVFJONKUSLSKSW-JTQLQIEISA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
Definitions
- This invention provides a method for treating or alleviating the symptoms of pathologic psychosis, comprising administering an effective amount of a cyano-oxime compound.
- the method of this invention provides a method for treating schizophrenia using compounds which were previously disclosed for use in the treatment of Alzheimer's Disease.
- the method of this invention provide the clinician with another treatment option for the treatment of psychotic conditions.
- the compounds used in the presently claimed method appear to have an acceptable side effect profile while providing surprising anti-psychotic activity.
- the present invention provides a method for treating a condition selected from the group consisting of schizophrenia, schizophreniform disorder, and schizoaffective disorder, comprising administering an effective amount of Compound I:
- the present invention provides a method for treating a pathologic psychotic condition selected from the group consisting of Conduct Disorder, Solitary Aggressive Type (312.00), Conduct Disorder, Undifferentiated Type (312.90), Tourette's Disorder (307.23), Chronic Motor Or Vocal Tic Disorder (307.22), Transient Tic Disorder (307.21), Tic Disorder NOS (307.20), Alcohol Withdrawal Delirium (291.00), Alcohol Hallucinosis (291.30), Alcohol Dementia Associated with Alcoholism (291.20), Amphetamine or Similarly Acting Sympathomimetic Intoxication (305.70), Amphetamine or Similarly Acting Sympathomimetic Delirium (292.81), Amphetamine or Similarly Acting Sympathomimetic Delusional Disorder (292.11), Cannabis Delusional Disorder (292.11), Cocaine Intoxication (305.60), Cocaine Delirium (292.81), Cocaine Delusional Disorder (292.11), Hallucinogen Hallucinosis (305.30), Hallucin
- Post-traumatic Stress Disorder (309.89), Generalized Anxiety Disorder (300.02), Anxiety Disorder NOS (300.00), Body Dysmorphic Disorder (300.70), Hypochondriasis (or Hypochondriacal Neurosis) (300.70), Somatization Disorder (300.81), Undifferentiated Somatoform Disorder (300.70), Somatoform Disorder NOS (300.70), Intermittent Explosive Disorder (312.34), Kleptomania (312.32), Pathological
- Schizophrenia Catatonic, Chronic with Acute Exacerbation (295.24), Schizophrenia, Catatonic, in Remission (295.55), Schizophrenia, Catatonic, Unspecified (295.20), Schizophrenia, Disorganized, Subchronic (295.11), Schizophrenia, Disorganized, Chronic (295.12),
- a particularly preferred Compound I is of the formula II:
- the compound may further be delivered by a variety of other pharmaceutically accepted routes including, but in no way limited to parenterally, subcutaneous, intranasal, intramuscular and intravenous routes.
- Such formulations may be designed to provide delayed or controlled release using formulation techniques which are known in the art.
- Arylcyclohexylamine Organic Mental Disorder NOS (292.90), Other or Unspecified Psychoactive Substance Intoxication (305.90), Other or Unspecified Psychoactive Substance Delirium (292.81), Other or Unspecified Psychoactive Substance Dementia (292.82), Other or Unspecified Psychoactive Substance Delusional Disorder (292.11), Other or Unspecified Psychoactive SubstanHallucinosis (292.12), Other or Unspecified Psychoactive Substance Mood Disorder (292.84), Other or Unspecified Psychoactive Substance Anxiety Disorder (292.89), Other or Unspecified Psychoactive Substance Personality Disorder (292.89), Other or Unspecified Psychoactive Substance Organic
- Obsessive Compulsive Disorder (300.30), Post-traumatic Stress Disorder (309.89), Generalized Anxiety Disorder (300.02), Anxiety Disorder NOS (300.00), Body Dysmorphic Disorder (300.70), Hypochondriasis (or Hypochondriacal Neurosis) (300.70), So atization Disorder (300.81),
- This activity can be demonstrated in models using well-established procedures.
- the compound is assessed in a number of standard behavioral tests predictive of antipsychotic activity.
- Antagonism of apomorphine-induced climbing in mice is predictive of antipsychotic activity (see, Moore, N.A. et al. Psychopharmacology 9 ⁇ (2), 263-266 (1988), and 96_ 539 (1988) ) .
- the conditioned avoidance model as described by Davidson, A.B. Differential Effect of Neuroleptic and other Psychotropic Agents on Acquisition of Avoidance in Rats, Life Sci . 1_8: 1279-1284 (1976) .
- conditioned avoidance test animals learn to respond during a conditioned stimulus in order to avoid mild shock presentation.
- a response during the conditioned stimulus is termed an avoidance response
- a response during shock is termed an escape response
- a response failure is when the animal fails to respond either during the conditioned stimulus or the shock presentation and is indicative of motor impairment.
- Animals rapidly learn to avoid 99% of the time.
- Antipsychotic drugs decrease the percentage of avoidance without interfering with the ability of the animal to respond since the animals do emit escape responses. The percentage of response failures is considered a measure of motor impairment. Procedure .
- Example 1 Human Clinical Trials The activity of Compound I for treating or alleviating psychosis can be demonstrated by human clinical trials.
- the study was designed as a double-blind, parallel, placebo-controlled multicenter trial. The patients are randomized into four groups, placebo and 3 other dosages of test compound. The dosages are administered orally with food. Patients are observed at four visits to provide baseline measurements. Visits 5-33 served as the treatment phase for the study.
- Treatment groups are compared with respect to the number and percent of patients who ever had the symptom during the double-blind portion of the study (visits 5 through 33) , at a severity that was worse than during the baseline visits (1 through 4) .
Abstract
The present invention provides a method for treating a condition selected from the group consisting of schizophrenia, schizoaffective disorder, and schizophreniform disorder in a patient using a Compound (I).
Description
METHOD FOR TREATING SCHIZOPHRENIA
This invention provides a method for treating or alleviating the symptoms of pathologic psychosis, comprising administering an effective amount of a cyano-oxime compound. The method of this invention provides a method for treating schizophrenia using compounds which were previously disclosed for use in the treatment of Alzheimer's Disease. The method of this invention provide the clinician with another treatment option for the treatment of psychotic conditions. The compounds used in the presently claimed method appear to have an acceptable side effect profile while providing surprising anti-psychotic activity.
The present invention provides a method for treating a condition selected from the group consisting of schizophrenia, schizophreniform disorder, and schizoaffective disorder, comprising administering an effective amount of Compound I:
or a pharmaceutically acceptable salt or solvate thereof.
The present invention provides a method for treating a pathologic psychotic condition selected from the group consisting of Conduct Disorder, Solitary Aggressive Type (312.00), Conduct Disorder, Undifferentiated Type (312.90), Tourette's Disorder (307.23), Chronic Motor Or Vocal Tic Disorder (307.22), Transient Tic Disorder (307.21), Tic Disorder NOS (307.20), Alcohol Withdrawal
Delirium (291.00), Alcohol Hallucinosis (291.30), Alcohol Dementia Associated with Alcoholism (291.20), Amphetamine or Similarly Acting Sympathomimetic Intoxication (305.70), Amphetamine or Similarly Acting Sympathomimetic Delirium (292.81), Amphetamine or Similarly Acting Sympathomimetic Delusional Disorder (292.11), Cannabis Delusional Disorder (292.11), Cocaine Intoxication (305.60), Cocaine Delirium (292.81), Cocaine Delusional Disorder (292.11), Hallucinogen Hallucinosis (305.30), Hallucinogen Delusional Disorder (292.11), Hallucinogen Mood Disorder (292.84), Hallucinogen Posthallucinogen Perception Disorder (292.89), Phencyclidine (PCP) or Similarly Acting Arylcyclohexylamine Intoxication (305.90), Phencyclidine (PCP) or Similarly Acting Arylcyclohexylamine Delirium (292.81), Phencyclidine (PCP) or Similarly Acting Arylcyclohexylamine Delusional Disorder (292.11), Phencyclidine (PCP) or Similarly Acting Arylcyclohexylamine Mood Disorder (292.84), Phencyclidine (PCP) or Similarly Acting Arylcyclohexylamine Organic Mental Disorder NOS (292.90), Other or Unspecified Psychoactive Substance Intoxication (305.90), Other or Unspecified Psychoactive Substance Delirium (292.81), Other or Unspecified Psychoactive Substance Dementia (292.82), Other or Unspecified Psychoactive Substance Delusional Disorder (292.11), Other or Unspecified Psychoactive SubstanHallucinosis (292.12), Other or Unspecified
Psychoactive Substance Mood Disorder (292.84), Other or Unspecified Psychoactive Substance Anxiety Disorder (292.89), Other or Unspecified Psychoactive Substance Personality Disorder (292.89), Other or Unspecified Psychoactive Substance Organic Mental Disorder NOS (292.90), Delirium (293.00), Dementia (294.10), Organic Delusional Disorder (293.81), Organic Hallucinosis (293.82), Organic Mood Disorder (293.83), Organic Anxiety Disorder (294.80), Organic Personality Disorder (310.10), Organic Mental Disorder (294.80), Obsessive Compulsive Disorder (300.30),
Post-traumatic Stress Disorder (309.89), Generalized Anxiety Disorder (300.02), Anxiety Disorder NOS (300.00), Body
Dysmorphic Disorder (300.70), Hypochondriasis (or Hypochondriacal Neurosis) (300.70), Somatization Disorder (300.81), Undifferentiated Somatoform Disorder (300.70), Somatoform Disorder NOS (300.70), Intermittent Explosive Disorder (312.34), Kleptomania (312.32), Pathological
Gambling (312.31), Pyro ania (312.33), Trichotillomania (312.39), and Impulse Control Disorder NOS (312.39); Schizophrenia, Catatonic, Subchronic, (295.21), Schizophrenia, Catatonic, Chronic (295.22), Schizophrenia, Catatonic, Subchronic with Acute Exacerbation (295.23),
Schizophrenia, Catatonic, Chronic with Acute Exacerbation (295.24), Schizophrenia, Catatonic, in Remission (295.55), Schizophrenia, Catatonic, Unspecified (295.20), Schizophrenia, Disorganized, Subchronic (295.11), Schizophrenia, Disorganized, Chronic (295.12),
Schizophrenia, Disorganized, Subchronic with Acute Exacerbation (295.13), Schizophrenia, Disorganized, Chronic with Acute Exacerbation (295.14), Schizophrenia, Disorganized, in Remission (295.15), Schizophrenia, Disorganized, Unspecified (295.10), Schizophrenia, Paranoid, Subchronic (295.31), Schizophrenia, Paranoid, Chronic (295.32), Schizophrenia, Paranoid, Subchronic with Acute Exacerbation (295.33), Schizophrenia, Paranoid, Chronic with Acute Exacerbation (295.34), Schizophrenia, Paranoid, in Remission (295.35), Schizophrenia, Paranoid, Unspecified (295.30), Schizophrenia, Undifferentiated, Subchronic (295.91), Schizophrenia, Undifferentiated, Chronic (295.92), Schizophrenia, Undifferentiated, Subchronic with Acute Exacerbation (295.93), Schizophrenia, Undifferentiated, Chronic with Acute Exacerbation (295.94), Schizophrenia, Undifferentiated, in Remission (295.95), Schizophrenia, Undifferentiated, Unspecified (295.90), Schizophrenia, Residual, Subchronic (295.61), Schizophrenia, Residual, Chronic (295.62), Schizophrenia, Residual, Subchronic with Acute Exacerbation (295.63), Schizophrenia, Residual,
Chronic with Acute Exacerbation (295.94), Schizophrenia, Residual, in Remission (295.65), Schizophrenia, Residual,
Unspecified (295.60), Delusional (Paranoid) Disorder (297.10), Brief Reactive Psychosis (298.80),
Schizophreniform Disorder (295.40), Schizoaffective Disorder (295.70), Induced Psychotic Disorder (297.30), Psychotic Disorder NOS (Atypical Psychosis) (298.90), Personality Disorders, Paranoid (301.00), Personality Disorders, Schizoid (301.20), Personality Disorders, Schizotypal (301.22), Personality Disorders, Antisocial (301.70), and Personality Disorders, Borderline (301.83) comprising administering an effective amount of Compound I or a pharmaceutically acceptable salt thereof.
As noted hereinbefore, the quinuclidine compound referred to herein as Compound I, employed in the method of the present invention is known. The compound, methods of preparing the compounds, as well as pharmaceutical formulations containing the compounds, are disclosed in issued United States Patent number 5,286,864 issued on February 15, 1994, herein incorporated by reference in its entirety. Thus, the artisan can readily prepare the Compound I materials described herein using the teachings in the published patent applications. To further clarify, Compound I shall refer to a compound of the structure:
or a pharmaceutically acceptable salt or solvate thereof. A particularly preferred Compound I is of the formula II:
WAL 2014.
The term "psychotic condition" refers to a condition wherein hallucinations, delusions, and/or confused thought process are characteristic manifestations of the named condition.
The term "pathologic" refers to a clinically significant disease state.
The term "effective amount", as used herein, represents an amount of compound necessary to prevent or treat a human susceptible to or suffering from a psychotic condition following administration to such human. The active compound is effective over a wide dosage range. For example, dosages per day will normally fall within the range of about 0.005 to about 500 mg/kg of body weight. In the treatment of adult humans, the range of about 0.05 to about 100 mg/kg, in single or divided doses, is preferred. However, it will be understood that the amount of the compound actually administered will be determined by a physician, in the light of the relevant circumstances including the condition to be treated, the choice of compound to be administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the chosen route of administration, and therefore the above dosage ranges are not intended to limit the scope of the invention in any way.
The compound may further be delivered by a variety of other pharmaceutically accepted routes including, but in no way limited to parenterally, subcutaneous, intranasal, intramuscular and intravenous routes. Such formulations may be designed to provide delayed or controlled release using formulation techniques which are known in the art.
As used herein the term "treating" includes prophylaxis of a physical and/or mental condition or amelioration or elimination of the developed physical and/or mental condition once it has been established or alleviation of the characteristic symptoms of such condition.
Pathologic psychological conditions which are psychoses or may be associated with psychotic features include, but are not limited to the following disorders which have been characterized in the DSM-III-R. Diagnostic and Statistical Manual of Mental Disorders, Revised, 3rd Ed. (1980) . The DSM-III-R was prepared by the Task Force on Nomenclature and Statistics of the American Psychiatric Association, and provides clear descriptions of diagnostic catagories. The numbers in parenthesis refer to the DSM-III-R categories. The skilled artisan will recognize that there are alternative nomenclatures, nosologies, and classification systems for pathologic psychological conditions and that these systems evolve with medical scientific progress. Examples of pathologic psychologic conditions which may be treated using Compound I include, but are not limited to, Conduct Disorder, Solitary Aggressive Type (312.00), Conduct Disorder, Undifferentiated Type (312.90), Tourette's Disorder (307.23), Chronic Motor Or Vocal Tic Disorder (307.22), Transient Tic Disorder
(307.21), Tic Disorder NOS (307.20), Alcohol Withdrawal Delirium (291.00), Alcohol Hallucinosis (291.30), Alcohol Dementia Associated with Alcoholism (291.20), Amphetamine or Similarly Acting Sympathomimetic Intoxication (305.70), Amphetamine or Similarly Acting Sympathomimetic Delirium (292.81), Amphetamine or Similarly Acting Sympathomimetic Delusional Disorder (292.11), Cannabis Delusional Disorder (292.11), Cocaine Intoxication (305.60), Cocaine Delirium (292.81), Cocaine Delusional Disorder (292.11), Hallucinogen Hallucinosis (305.30), Hallucinogen Delusional Disorder (292.11), Hallucinogen Mood Disorder (292.84), Hallucinogen Posthallucinogen Perception Disorder (292.89), Phencyclidine (PCP) or_ Similarly Acting Arylcyclohexylamine Intoxication (305.90), Phencyclidine (PCP) or Similarly Acting
Arylcyclohexylamine Delirium (292.81), Phencyclidine (PCP) or Similarly Acting Arylcyclohexylamine Delusional
Disorder (292.11), Phencyclidine (PCP) or Similarly Acting Arylcyclohexylamine Mood Disorder (292.84), Phencyclidine (PCP) or Similarly Acting
Arylcyclohexylamine Organic Mental Disorder NOS (292.90), Other or Unspecified Psychoactive Substance Intoxication (305.90), Other or Unspecified Psychoactive Substance Delirium (292.81), Other or Unspecified Psychoactive Substance Dementia (292.82), Other or Unspecified Psychoactive Substance Delusional Disorder (292.11), Other or Unspecified Psychoactive SubstanHallucinosis (292.12), Other or Unspecified Psychoactive Substance Mood Disorder (292.84), Other or Unspecified Psychoactive Substance Anxiety Disorder (292.89), Other or Unspecified Psychoactive Substance Personality Disorder (292.89), Other or Unspecified Psychoactive Substance Organic
Mental Disorder NOS (292.90), Delirium (293.00), Dementia (294.10), Organic Delusional Disorder (293.81), Organic Hallucinosis (293.82), Organic Mood Disorder (293.83), Organic Anxiety Disorder (294.80), Organic Personality Disorder (310.10), Organic Mental Disorder (294.80),
Obsessive Compulsive Disorder (300.30), Post-traumatic Stress Disorder (309.89), Generalized Anxiety Disorder (300.02), Anxiety Disorder NOS (300.00), Body Dysmorphic Disorder (300.70), Hypochondriasis (or Hypochondriacal Neurosis) (300.70), So atization Disorder (300.81),
Undifferentiated Somatoform Disorder (300.70), Somatoform Disorder NOS (300.70), Intermittent Explosive Disorder (312.34), Kleptomania (312.32), Pathological Gambling (312.31), Pyromania (312.33), Trichotillomania (312.39), and Impulse Control Disorder NOS (312.39); Schizophrenia, Catatonic, Subchronic, (295.21), Schizophrenia, Catatonic, Chronic (295.22), Schizophrenia, Catatonic, Subchronic with Acute Exacerbation (295.23), Schizophrenia, Catatonic, Chronic with Acute Exacerbation (295.24), Schizophrenia, Catatonic, in Remission
(295.55), Schizophrenia, Catatonic, Unspecified (295.20), Schizophrenia, Disorganized, Subchronic (295.11),
Schizophrenia, Disorganized, Chronic (295.12), Schizophrenia, Disorganized, Subchronic with Acute Exacerbation (295.13), Schizophrenia, Disorganized, Chronic with Acute Exacerbation (295.14), Schizophrenia, Disorganized, in Remission (295.15), Schizophrenia, Disorganized, Unspecified (295.10), Schizophrenia, Paranoid, Subchronic (295.31), Schizophrenia, Paranoid, Chronic (295.32), Schizophrenia, Paranoid, Subchronic with Acute Exacerbation (295.33), Schizophrenia, Paranoid, Chronic with Acute Exacerbation (295.34), Schizophrenia, Paranoid, in Remission (295.35), Schizophrenia, Paranoid, Unspecified (295.30), Schizophrenia, Undifferentiated, Subchronic (295.91), Schizophrenia, Undifferentiated, Chronic (295.92), Schizophrenia, Undifferentiated, Subchronic with Acute Exacerbation (295.93), Schizophrenia, Undifferentiated, Chronic with Acute Exacerbation (295.94), Schizophrenia, Undifferentiated, in Remission (295.95), Schizophrenia, Undifferentiated, Unspecified (295.90), Schizophrenia, Residual, Subchronic (295.61), Schizophrenia, Residual, Chronic (295.62), Schizophrenia, Residual, Subchronic with Acute Exacerbation (295.63), Schizophrenia, Residual, Chronic with Acute Exacerbation (295.94), Schizophrenia, Residual, in Remission (295.65), Schizophrenia, Residual, Unspecified (295.60), Delusional (Paranoid) Disorder (297.10), Brief Reactive Psychosis (298.80), Schizophreniform Disorder (295.40), Schizoaffective Disorder (295.70), Induced Psychotic Disorder (297.30), Psychotic Disorder NOS (Atypical Psychosis) (298.90), Personality Disorders, Paranoid (301.00), Personality Disorders, Schizoid (301.20), Personality Disorders, Schizotypal (301.22), Personality Disorders, Antisocial (301.70), and Personality Disorders, Borderline (301.83) As mentioned above, Compound I has useful antipsychotic activity. This activity can be demonstrated in models using well-established procedures. For
example, the compound is assessed in a number of standard behavioral tests predictive of antipsychotic activity. Antagonism of apomorphine-induced climbing in mice is predictive of antipsychotic activity (see, Moore, N.A. et al. Psychopharmacology 9^ (2), 263-266 (1988), and 96_ 539 (1988) ) . Further, the conditioned avoidance model, as described by Davidson, A.B. Differential Effect of Neuroleptic and other Psychotropic Agents on Acquisition of Avoidance in Rats, Life Sci . 1_8: 1279-1284 (1976) . One of the major pharmacological properties of currently employed clinical antipsychotic drugs in animals is their ability to block conditioned avoidance responding (Cook and Davidson, Psychopharmacology, A Generation of Progress, (Raven Press, New York: 1978) pp 563-567; Davidson and Weidley, Life Sci. 18:1279-1284, 1976) .
There is a high correlation between their activity and potency on a conditioned avoidance test and their clinical efficacy and potencies as antipsychotic drugs (Creese et al, Dopamine receptor binding predicts clinical and pharmacological properties of anti schizophreni c drugs Science 192:481-483, 1976).
In the conditioned avoidance test, animals learn to respond during a conditioned stimulus in order to avoid mild shock presentation. A response during the conditioned stimulus is termed an avoidance response, a response during shock is termed an escape response; a response failure is when the animal fails to respond either during the conditioned stimulus or the shock presentation and is indicative of motor impairment. Animals rapidly learn to avoid 99% of the time. Antipsychotic drugs decrease the percentage of avoidance without interfering with the ability of the animal to respond since the animals do emit escape responses. The percentage of response failures is considered a measure of motor impairment.
Procedure .
Rats were required to press a response lever in an experimental chamber in order to avoid or escape foot- shock. Each experimental session consisted of 50 trials. During each trial, the chamber was illuminated and a tone presented for a maximum of 10 seconds. A response during the tone immediately terminated the tone and the houselight, ending the trial. In the absence of a response during the tone alone, tone plus foot shock (2.0 mA) was presented for a maximum of 10 seconds. A response during shock presentation immediately terminated the shock, the tone and the houselight, ending the trial. Such studies suggest that Compound I may be especially desirable for the treatment of schizophrenia.
The following Examples are studies to establish the usefulness of the named compounds for treating such psychotic conditions.
Example 1 Human Clinical Trials The activity of Compound I for treating or alleviating psychosis can be demonstrated by human clinical trials. The study was designed as a double-blind, parallel, placebo-controlled multicenter trial. The patients are randomized into four groups, placebo and 3 other dosages of test compound. The dosages are administered orally with food. Patients are observed at four visits to provide baseline measurements. Visits 5-33 served as the treatment phase for the study.
During the visits, patients are observed for signs of agitation, mood swings, tremor, delirium, social withdrawal, and concentration abilities. These behaviors are indicative of the effect of the test compound on psychotic conditions.
Treatment groups are compared with respect to the number and percent of patients who ever had the symptom during the double-blind portion of the study (visits 5 through 33) , at a severity that was worse than during the baseline visits (1 through 4) .
Claims
1. A method for treating in a patient suffering from a condition selected from the group consisting of schizophrenia, schizophreniform disorder, and schizoaffective disorder comprising administering to a patient in need thereof, an effective amount of a Compound I: Compound I :
or a pharmaceutically acceptable salt or solvate thereof.
2. A method of Claim 1 wherein the Compound I is
3. A method of Claim 2 wherein the effective amount is from 1 mg/kg to about 100 mg/kg per day.
4. A method of Claim 1 wherein the effective amount is delivered using a transdermal patch.
5. A method of Claim 4 wherein the transdermal patch delivers from about 10 to about 100 mg of base compound per day.
6. A method of Claim 5 wherein the transdermal patch delivers an effective amount for one (1) to seven (7 days .
7.A method for treating in a patient suffering from a pathologic psychotic condition comprising administering to a patient in need thereof, an effective amount of a Compound I:
or a pharmaceutically acceptable salt thereof.
8. A method of Claim 7 wherein the pathologic psychotic condition is selected from the group consisting of Conduct Disorder, Solitary Aggressive Type (312.00), Conduct Disorder, Undifferentiated Type (312.90), Tourette's Disorder (307.23), Chronic Motor Or Vocal Tic Disorder (307.22), Transient Tic Disorder (307.21), Tic Disorder NOS (307.20), Alcohol Withdrawal Delirium (291.00), Alcohol Hallucinosis (291.30), Alcohol Dementia Associated with Alcoholism (291.20), Amphetamine or Similarly Acting Sympathomimetic Intoxication (305.70), Amphetamine or Similarly Acting Sympathomimetic Delirium (292.81), Amphetamine or Similarly Acting Sympathomimetic Delusional Disorder (292.11), Cannabis Delusional Disorder (292.11), Cocaine Intoxication (305.60), Cocaine Delirium (292.81), Cocaine Delusional Disorder (292.11), Hallucinogen Hallucinosis (305.30), Hallucinogen Delusional Disorder (292.11), Hallucinogen Mood Disorder (292.84), Hallucinogen Posthallucinogen Perception Disorder (292.89), Phencyclidine (PCP) or Similarly Acting Arylcyclohexylamine Intoxication (305.90), Phencyclidine (PCP) or Similarly Acting Arylcyclohexylamine Delirium (292.81), Phencyclidine (PCP) or Similarly Acting Arylcyclohexylamine Delusional Disorder (292.11), Phencyclidine (PCP) or Similarly Acting Arylcyclohexylamine Mood Disorder (292.84), Phencyclidine (PCP) or Similarly Acting Arylcyclohexylamine Organic Mental Disorder NOS (292.90), Other or Unspecified Psychoactive Substance Intoxication (305.90), Other or Unspecified Psychoactive Substance Delirium (292.81), Other or Unspecified Psychoactive Substance Dementia (292.82), Other or Unspecified Psychoactive Substance Delusional Disorder (292.11), Other or Unspecified Psychoactive SubstanHallucinosis (292.12), Other or Unspecified
Psychoactive Substance Mood Disorder (292.84), Other or Unspecified Psychoactive Substance Anxiety Disorder (292.89), Other or Unspecified Psychoactive Substance Personality Disorder (292.89), Other or Unspecified Psychoactive Substance Organic Mental Disorder NOS (292.90), Delirium (293.00), Dementia (294.10), Organic Delusional Disorder (293.81), Organic Hallucinosis (293.82), Organic Mood Disorder (293.83), Organic Anxiety Disorder (294.80), Organic Personality Disorder (310.10), Organic Mental Disorder (294.80), Obsessive Compulsive Disorder (300.30),
Post-traumatic Stress Disorder (309.89), Generalized Anxiety Disorder (300.02), Anxiety Disorder NOS (300.00), Body Dysmorphic Disorder (300.70), Hypochondriasis (or Hypochondriacal Neurosis) (300.70), Somatization Disorder (300.81), Undifferentiated Somatoform Disorder (300.70), Somatoform Disorder NOS (300.70), Intermittent Explosive Disorder (312.34), Kleptomania (312.32), Pathological Gambling (312.31), Pyromania (312.33), Trichotillomania (312.39), and Impulse Control Disorder NOS (312.39); Schizophrenia, Catatonic, Subchronic, (295.21),
Schizophrenia, Catatonic, Chronic (295.22), Schizophrenia, Catatonic, Subchronic with Acute Exacerbation (295.23), Schizophrenia, Catatonic, Chronic with Acute Exacerbation (295.24), Schizophrenia, Catatonic, in Remission (295.55), Schizophrenia, Catatonic, Unspecified (295.20),
Schizophrenia, Disorganized, Subchronic (295.11), Schizophrenia, Disorganized, Chronic (295.12), Schizophrenia, Disorganized, Subchronic with Acute Exacerbation (295.13), Schizophrenia, Disorganized, Chronic with Acute Exacerbation (295.14), Schizophrenia, Disorganized, in Remission (295.15), Schizophrenia, Disorganized, Unspecified (295.10), Schizophrenia, Paranoid, Subchronic (295.31), Schizophrenia, Paranoid, Chronic (295.32), Schizophrenia, Paranoid, Subchronic with Acute Exacerbation (295.33), Schizophrenia, Paranoid, Chronic with Acute Exacerbation (295.34), Schizophrenia, Paranoid, in Remission (295.35), Schizophrenia, Paranoid, Unspecified (295.30), Schizophrenia, Undifferentiated, Subchronic (295.91), Schizophrenia, Undifferentiated, Chronic (295.92), Schizophrenia, Undifferentiated, Subchronic with Acute Exacerbation (295.93), Schizophrenia, Undifferentiated, Chronic with Acute Exacerbation (295.94), Schizophrenia, Undifferentiated, in Remission (295.95), Schizophrenia, Undifferentiated, Unspecified (295.90), Schizophrenia, Residual, Subchronic (295.61), Schizophrenia, Residual, Chronic (295.62), Schizophrenia, Residual, Subchronic with Acute Exacerbation (295.63), Schizophrenia, Residual,
Chronic with Acute Exacerbation (295.94), Schizophrenia, Residual, in Remission (295.65), Schizophrenia, Residual, Unspecified (295.60), Delusional (Paranoid) Disorder (297.10), Brief Reactive Psychosis (298.80), Schizophreniform Disorder (295.40), Schizoaffective Disorder (295.70), Induced Psychotic Disorder (297.30), Psychotic Disorder NOS (Atypical Psychosis) (298.90), Personality Disorders, Paranoid (301.00), Personality Disorders, Schizoid (301.20), Personality Disorders, Schizotypal (301.22), Personality Disorders, Antisocial (301.70), and Personality Disorders, Borderline (301.83).
9. Use of a Compound I
or a pharmaceutically acceptable salt or solvate thereof, optionally in combination with a pharmaceutically acceptable excipient, for the preparation of a pharmaceutical composition for treating a patient suffering from a condition selected from the group consisting of schizophrenia, schizophreniform disorder, and schizoaffective disorder.
10. The use according to claim 9 wherein the Compound I is :
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU68960/98A AU6896098A (en) | 1997-04-11 | 1998-04-08 | Method for treating schizophrenia |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4357097P | 1997-04-11 | 1997-04-11 | |
| US60/043,570 | 1997-04-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1998046225A1 true WO1998046225A1 (en) | 1998-10-22 |
Family
ID=21927829
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1998/007152 WO1998046225A1 (en) | 1997-04-11 | 1998-04-08 | Method for treating schizophrenia |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU6896098A (en) |
| WO (1) | WO1998046225A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002064124A2 (en) * | 2001-02-15 | 2002-08-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Medicament formulation containing a muscarinic agonist |
| US10154988B2 (en) | 2012-11-14 | 2018-12-18 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5451587A (en) * | 1988-11-22 | 1995-09-19 | Boehringer Ingelheim Gmbh | Quinuclidines, their use as medicaments and processes for their preparation |
-
1998
- 1998-04-08 AU AU68960/98A patent/AU6896098A/en not_active Abandoned
- 1998-04-08 WO PCT/US1998/007152 patent/WO1998046225A1/en active Application Filing
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5451587A (en) * | 1988-11-22 | 1995-09-19 | Boehringer Ingelheim Gmbh | Quinuclidines, their use as medicaments and processes for their preparation |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002064124A2 (en) * | 2001-02-15 | 2002-08-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Medicament formulation containing a muscarinic agonist |
| WO2002064124A3 (en) * | 2001-02-15 | 2002-12-05 | Boehringer Ingelheim Pharma | Medicament formulation containing a muscarinic agonist |
| US10154988B2 (en) | 2012-11-14 | 2018-12-18 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| EP3610890A1 (en) | 2012-11-14 | 2020-02-19 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| US10624875B2 (en) | 2012-11-14 | 2020-04-21 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
Also Published As
| Publication number | Publication date |
|---|---|
| AU6896098A (en) | 1998-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sloan et al. | Fluoxetine as a treatment for emotional lability after brain injury | |
| CN111278440B (en) | Method of treating amyotrophic lateral sclerosis with pridopidine | |
| TWI549678B (en) | Use of 4-aminopyridine to improve neuro-cognitive and/or neuro-psychiatric impairment in patients with demyelinating and other nervous system conditions | |
| JP2009535367A (en) | Use of escitalopram to improve cognition | |
| WO2016059571A1 (en) | Combinations comprising siponimod and laquinimod for the treatment of multiple sclerosis | |
| US6284771B1 (en) | Method for treating schizophrenia | |
| PT1051170E (en) | USE OF AMINOMETILCHROMANS SUBSTITUTED FOR THE PREVENTION OF NEURONAL DEGENERATION AND FOR THE PROMOTION OF NEURONAL REGENERATION | |
| WO2007125290A1 (en) | Mono and combination therapy of m1/m4 agonist (sabcomeline) for treatment of negative symptoms of schizophrenia | |
| EP1778211A1 (en) | Methods and materials for treating mental illness | |
| KR20130131265A (en) | Composition for preventing or treating irritable bowel syndrome | |
| US10300068B2 (en) | Method of treating insomnia | |
| WO1998046225A1 (en) | Method for treating schizophrenia | |
| EP0363403A1 (en) | Medicament for schizophrenia | |
| CN111973592A (en) | Methods of treating amyotrophic lateral sclerosis and neuropathy | |
| EP4243797A1 (en) | Rapidly infusing platform and compositions for therapeutic treatment in humans | |
| KR20020016944A (en) | Medicinal Compositions for Treating Lower Uropathy | |
| PFEFFERBAUM et al. | Narcolepsy, paranoid psychosis, and tardive dyskinesia: a pharmacological dilemma | |
| EP0821955B1 (en) | Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline) for treating bipolar disorder | |
| EP1901726A2 (en) | Composition for treatment of psychosis | |
| RU2805061C2 (en) | Treatment of demyelinating diseases | |
| US20020198172A1 (en) | Method of treating motor neuron diseases and demyelinating diseases with citicoline | |
| WO2022041123A1 (en) | Application of sesquiterpene lactone in preparing drug for treating optic neuritis | |
| EP0934040A1 (en) | Method for treating dementia due to aids | |
| CN115103676A (en) | Combination therapy using pridopidine and another activator for treating amyotrophic lateral | |
| WO1998026778A1 (en) | Remedies/preventives for abnormal motions accompanying disorders in extrapyramidal system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 09381126 Country of ref document: US |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 1998544063 Format of ref document f/p: F |
|
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: CA |